Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for NK Cell Checkpoint Inhibition.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for KIR2DL3 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | KIR2DL3 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View KIR2DL3 Products |
| Gene Delivery | KIR2DL3 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View KIR2DL3 Products |
| Benchmark Ab | Anti-KIR2DL3 (Sequence of Lirilumab) Recombinant positive control. |
View KIR2DL3 Products |
| Validator | KIR2DL3 siRNA Set For knockdown verification. |
View KIR2DL3 Products |
| Related Target A | KIR2DL1 Critical for family selectivity and cross-reactivity counter-screening. |
View KIR2DL1 Products |
| Related Target B | HLA-C Natural ligand of KIR2DL3, essential for ligand-blocking and competitive binding assays. |
View HLA-C Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-reactivity & Selectivity Profiling | Human/Cyno ortholog proteins available with >95% purity, enabling high-resolution affinity mapping |
| KIR Subfamily Counter Screening | Homolog panel proteins (KIR2DL1, KIR2DL2) strictly verified by mass spectrometry to guarantee sequence identity |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay calibration |
| False Positives | Validated siRNA included for target-specific knockdown verification |
Live KIR2DL3/CD158b2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for KIR2DL3 therapeutics is intensifying, with major players shifting focus from traditional mAbs to multi-specific NK cell engagers (NKCEs). As first-generation therapies reach the clinic, the next wave of R&D is targeting synergistic NK-cell checkpoint combinations and bispecific constructs that bridge NK cells directly to tumor-associated antigens.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (mAbs) | Innate Pharma, Bristol Myers Squibb | Solid Tumors, Hematological Malignancies | Ligand-blocking Assay (Need high-purity ECD-Fc & HLA-C ligands) |
| NK Cell Engagers (NKCEs) | Sanofi, Affimed | Relapsed/Refractory Lymphoma | Multi-specific Binding Validation (Need cross-reactive antigens & CD16a) |
| Cell Therapies (CAR-NK) | Fate Therapeutics, Nkarta | Advanced Solid Tumors | Stable Cell Line Construction (Need Lentivirus for high-efficiency transduction) |